文献速递核素与放射性配体治疗放射性药物与辐射防护

锝与铼诊疗一体化的潜力

Potential of Technetium and Rhenium Theranostics.
PubMed 文献 · Semin Nucl Med · 2025-02-24

本文讨论诊疗一体化对真正诊疗配对的需求及当前障碍,指出以PET/CT为基础的诊疗一体化存在可及性不平等,68Ga和177Lu需求增长对全球生产造成压力。作者提出,广泛可用的发生器生产99mTc用于显像、188Re用于治疗,可能有助于解决健康不平等缺口并改善结局。

要点

  • 以PET/CT为基础的诊疗一体化因社会经济和地理因素造成可及性与机会不平等。
  • 68Ga和177Lu需求增长正给全球生产能力带来压力。
  • 99mTc/188Re诊疗一体化可能有助于解决先进诊疗一体化可及性与机会的不平等。

核心结论

  • 99mTc/188Re诊疗一体化可能有助于解决先进诊疗一体化可及性与机会的不平等。

研究设计与样本

  • 本文为综述,讨论诊疗一体化中真正诊疗配对的发展潜力及当前应用障碍。

主要发现

  • 以PET/CT作为诊疗一体化诊断配对的基石,因社会经济和地理因素造成可及性与机会不平等。
  • 68Ga和177Lu需求增长正给全球生产能力带来压力。
  • 广泛可用的发生器生产99mTc可用于显像、188Re可用于治疗,此方法尚不成熟但可能解决健康不平等缺口并改善结局。
  • 尽管放射化学性质有利且近乎相同,下一代诊疗放射性核素配对的探索很少提及锝或铼放射性核素。
  • SPECT/CT仪器与放射化学的进步为向无PET诊疗一体化服务的社区提供诊疗一体化带来机会。

关键数值与推荐

  • 188Re和99mTc通过发生器每日淋洗供应,提供显著便利性、灵活性及延迟生物分子显像。
  • 188Re的低丰度伽马发射允许连续显像和剂量学计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While theranostics has transformed the precision medicine landscape over the last decade, there is scope for the development of true theranostic pairs, e.g. diagnostic and therapeutic partners in which any physical, chemical, and biological differences are negligible to in vivo application. Although simple to state in theory, there are, in fact, limited options exhibiting optimal physical characteristics and wholly shared elements. Further compounding real-world application of the traditional theranostic method are additional barriers. The use of PET/CT as the cornerstone of the diagnostic pair in theranostics creates inequity of access and opportunity based on socioeconomic and geographic factors, and the growing demand for both 68Ga and 177Lu is straining production capabilities globally. Improving access to theranostics globally will require novel thinking and infrastructure investment to ensure that patients of all economic and social backgrounds have access to this transformative technology. An approach which is underdeveloped, but which may address gaps in health inequities and improve outcomes, is the application of the widely available generator-produced 99mTc for imaging and 188Re for therapy. Despite favourable and near identical radiochemistry, the search for the next generation of theranostic radionuclide pairs seldom references technetium or rhenium radionuclides. Advances in SPECT/CT instrumentation and radiochemistry provide an opportunity to deliver theranostics to communities not serviced by PET-based theranostics. The 188Re and 99mTc supply by daily elution of a generator affords significant convenience, flexibility and delayed biomolecule imaging. Low abundance gamma emissions of 188Re allow serial imaging and dosimetry calculations. 99mTc / 188Re theranostics could address inequity in access and opportunity to cutting edge theranostics.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Currie GM, Rohren EM. Potential of Technetium and Rhenium Theranostics. Semin Nucl Med. 2025. PMID: 40000268. doi:10.1053/j.semnuclmed.2025.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。